NASDAQ:BGMS

Cyclacel Pharmaceuticals Q4 2025 Earnings Results & Report

Cyclacel Pharmaceuticals logo
$0.61 +0.04 (+6.28%)
Closing price 03:59 PM Eastern
Extended Trading
$0.65 +0.04 (+7.06%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cyclacel Pharmaceuticals reported Q4 2025 earnings on March 30, 2026. The company reported EPS of -$2.21, while revenue was $670 thousand.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Cyclacel Pharmaceuticals EPS Results

Actual EPS
-$2.21
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cyclacel Pharmaceuticals Revenue Results

Actual Revenue
$670 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Cyclacel Pharmaceuticals Q4 2025 Earnings FAQ

Cyclacel Pharmaceuticals (NASDAQ:BGMS) reported earnings of -$2.21 per share for Q4 2025. The report was announced on Monday, March 30, 2026.

Cyclacel Pharmaceuticals reported revenue of $670 thousand for Q4 2025.

Cyclacel Pharmaceuticals Earnings Headlines

Cyclacel Pharmaceuticals (NASDAQ:BGMS) Stock Falls 9.3% - Should You Sell?
$0. Later: $29.97.
Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
See More Cyclacel Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclacel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclacel Pharmaceuticals and other key companies, straight to your email.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (NASDAQ:BGMS) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research has centered on compounds that target cell-cycle regulation and other processes involved in cancer-cell growth.

The company’s investigational drug candidates have included fadraciclib, a cyclin-dependent kinase inhibitor, and sapacitabine, an oral nucleoside analogue. These candidates have been studied for potential use in hematologic cancers and solid tumors; they are not approved medicines.

Founded in the United Kingdom, Cyclacel has operated in both the U.K. and the United States. Spiro Rombotis has served as the company’s president and chief executive officer.

View Cyclacel Pharmaceuticals Profile